TDMS Study 05180-07 Pathology Tables
NTP Experiment-Test: 05180-07 INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a) Report: PEIRPT05
Study Type: CHRONIC GALLIUM ARSENIDE Date: 03/09/99
Route: RESPIRATORY EXPOSURE WHOLE BODY Time: 14:24:40
2 YEAR CHRONIC MICE
Facility: Battelle Northwest
Chemical CAS #: 1303-00-0000
Lock Date: 04/11/97
Cage Range: All
Reasons For Removal: All
Removal Date Range: All
Treatment Groups: Include All
a Number of animals examined microscopically at site and number of animals with lesion
Page 1
NTP Experiment-Test: 05180-07 INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a) Report: PEIRPT05
Study Type: CHRONIC GALLIUM ARSENIDE Date: 03/09/99
Route: RESPIRATORY EXPOSURE WHOLE BODY Time: 14:24:40
____________________________________________________________________________________________________________________________________
B6C3F1 MICE FEMALE CONTROL 0.1 0.5 1.0
MG/M3 MG/M3 MG/M3
____________________________________________________________________________________________________________________________________
DISPOSITION SUMMARY
Animals Initially in Study 50 50 50 50
Early Deaths
Moribund Sacrifice 11 11 16 11
Natural Death 3 3 2 10
Accidently Killed 2 1
Survivors
Terminal Sacrifice 36 34 31 29
Animals Examined Microscopically 50 50 50 50
____________________________________________________________________________________________________________________________________
ALIMENTARY SYSTEM
Gallbladder (47) (45) (45) (41)
Intestine Small, Duodenum (48) (47) (50) (46)
Intestine Small, Jejunum (48) (47) (49) (43)
Carcinoma 1 (2%)
Polyp Adenomatous 1 (2%)
Liver (50) (50) (50) (50)
Hepatocellular Carcinoma 8 (16%) 9 (18%) 4 (8%) 5 (10%)
Hepatocellular Carcinoma, Multiple 4 (8%) 2 (4%) 3 (6%)
Hepatocellular Adenoma 9 (18%) 9 (18%) 12 (24%) 8 (16%)
Hepatocellular Adenoma, Multiple 2 (4%) 1 (2%) 2 (4%)
Hepatocholangiocarcinoma 2 (4%)
Hepatocholangiocarcinoma, Multiple 1 (2%)
Histiocytic Sarcoma 1 (2%)
Mesentery (8) (9) (16) (13)
Hemangiosarcoma 1 (6%)
Hepatocholangiocarcinoma, Metastatic, Liver 1 (6%) 1 (8%)
Sarcoma, Metastatic, Skin 2 (25%) 1 (8%)
Teratoma Malignant, Metastatic, Ovary 1 (6%)
Pancreas (50) (50) (50) (49)
Sarcoma, Metastatic, Skin 2 (4%)
Salivary Glands (50) (50) (50) (50)
Stomach, Forestomach (49) (50) (50) (49)
Squamous Cell Papilloma 3 (6%)
____________________________________________________________________________________________________________________________________
CARDIOVASCULAR SYSTEM
Heart (50) (50) (50) (50)
Hemangiosarcoma 1 (2%)
Hepatocholangiocarcinoma, Metastatic, Liver 1 (2%)
____________________________________________________________________________________________________________________________________
NTP Experiment-Test: 05180-07 INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a) Report: PEIRPT05
Study Type: CHRONIC GALLIUM ARSENIDE Date: 03/09/99
Route: RESPIRATORY EXPOSURE WHOLE BODY Time: 14:24:40
____________________________________________________________________________________________________________________________________
B6C3F1 MICE FEMALE CONTROL 0.1 0.5 1.0
MG/M3 MG/M3 MG/M3
____________________________________________________________________________________________________________________________________
ENDOCRINE SYSTEM
Adrenal Medulla (50) (49) (50) (49)
Pheochromocytoma Benign 1 (2%) 1 (2%)
Islets, Pancreatic (50) (50) (50) (48)
Adenoma 1 (2%)
Pituitary Gland (46) (48) (50) (47)
Pars Distalis, Adenoma 3 (7%) 7 (15%) 5 (10%) 7 (15%)
Pars Distalis, Carcinoma 1 (2%)
Pars Intermedia, Adenoma 2 (4%)
Pars Intermedia, Carcinoma 2 (4%)
Thyroid Gland (50) (50) (50) (49)
Hepatocholangiocarcinoma, Metastatic, Liver 1 (2%)
C-Cell, Carcinoma 1 (2%)
Follicular Cell, Adenoma 1 (2%) 2 (4%)
Follicular Cell, Carcinoma 2 (4%)
____________________________________________________________________________________________________________________________________
GENERAL BODY SYSTEM
None
____________________________________________________________________________________________________________________________________
GENITAL SYSTEM
Ovary (49) (50) (50) (46)
Cystadenoma 2 (4%) 1 (2%) 1 (2%) 3 (7%)
Sarcoma, Metastatic, Skin 1 (2%)
Teratoma Malignant 1 (2%)
Thecoma Benign 1 (2%)
Tubulostromal Adenoma 1 (2%)
Uterus (49) (50) (50) (50)
Carcinoma 1 (2%)
Hemangioma 1 (2%)
Leiomyoma 1 (2%) 1 (2%)
Leiomyosarcoma 1 (2%)
Polyp Stromal 1 (2%) 2 (4%) 2 (4%) 2 (4%)
Sarcoma Stromal 1 (2%)
____________________________________________________________________________________________________________________________________
HEMATOPOIETIC SYSTEM
Bone Marrow (50) (50) (50) (50)
Hemangiosarcoma 1 (2%) 1 (2%)
Lymph Node (4) (8) (5) (6)
Sarcoma, Metastatic, Skin 1 (25%) 1 (17%)
Teratoma Malignant, Metastatic, Ovary 1 (20%)
Pancreatic, Hepatocholangiocarcinoma,
NTP Experiment-Test: 05180-07 INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a) Report: PEIRPT05
Study Type: CHRONIC GALLIUM ARSENIDE Date: 03/09/99
Route: RESPIRATORY EXPOSURE WHOLE BODY Time: 14:24:40
____________________________________________________________________________________________________________________________________
B6C3F1 MICE FEMALE CONTROL 0.1 0.5 1.0
MG/M3 MG/M3 MG/M3
____________________________________________________________________________________________________________________________________
HEMATOPOIETIC SYSTEM - cont
Metastatic, Liver 1 (17%)
Lymph Node, Bronchial (39) (43) (42) (42)
Hepatocholangiocarcinoma, Metastatic, Liver 1 (2%)
Histiocytic Sarcoma 1 (3%)
Lymph Node, Mandibular (35) (37) (43) (43)
Lymph Node, Mesenteric (49) (49) (50) (47)
Hemangiosarcoma 1 (2%)
Hepatocholangiocarcinoma, Metastatic, Liver 1 (2%)
Histiocytic Sarcoma 1 (2%)
Sarcoma, Metastatic, Skin 1 (2%)
Lymph Node, Mediastinal (40) (43) (49) (45)
Carcinoma, Metastatic, Harderian Gland 1 (3%)
Hepatocholangiocarcinoma, Metastatic, Liver 1 (2%) 2 (4%)
Sarcoma, Metastatic, Skin 1 (3%)
Spleen (50) (50) (50) (49)
Hemangiosarcoma 2 (4%) 2 (4%)
Histiocytic Sarcoma 1 (2%)
Thymus (43) (47) (43) (44)
Hepatocholangiocarcinoma, Metastatic, Liver 1 (2%)
____________________________________________________________________________________________________________________________________
INTEGUMENTARY SYSTEM
Mammary Gland (50) (50) (50) (49)
Carcinoma 1 (2%) 1 (2%) 1 (2%) 2 (4%)
Skin (50) (50) (50) (50)
Subcutaneous Tissue, Carcinoma 1 (2%)
Subcutaneous Tissue, Hemangioma 1 (2%)
Subcutaneous Tissue, Sarcoma 4 (8%) 4 (8%) 2 (4%) 4 (8%)
Subcutaneous Tissue, Schwannoma Benign 1 (2%)
____________________________________________________________________________________________________________________________________
MUSCULOSKELETAL SYSTEM
Bone (50) (50) (50) (50)
Hemangiosarcoma 1 (2%)
Skeletal Muscle (1) (2) (1) (1)
Carcinoma, Metastatic, Harderian Gland 1 (100%)
Hemangiosarcoma 1 (100%)
Hepatocholangiocarcinoma, Metastatic, Liver 1 (100%)
____________________________________________________________________________________________________________________________________
NTP Experiment-Test: 05180-07 INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a) Report: PEIRPT05
Study Type: CHRONIC GALLIUM ARSENIDE Date: 03/09/99
Route: RESPIRATORY EXPOSURE WHOLE BODY Time: 14:24:40
____________________________________________________________________________________________________________________________________
B6C3F1 MICE FEMALE CONTROL 0.1 0.5 1.0
MG/M3 MG/M3 MG/M3
____________________________________________________________________________________________________________________________________
NERVOUS SYSTEM
Brain (50) (50) (50) (50)
Carcinoma, Metastatic, Pituitary Gland 3 (6%)
Oligodendroglioma Benign 1 (2%)
____________________________________________________________________________________________________________________________________
RESPIRATORY SYSTEM
Larynx (50) (50) (50) (50)
Lung (50) (50) (50) (50)
Alveolar/Bronchiolar Adenoma 6 (12%) 4 (8%) 1 (2%) 3 (6%)
Alveolar/Bronchiolar Carcinoma 1 (2%) 3 (6%) 2 (4%)
Alveolar/Bronchiolar Carcinoma, Multiple 1 (2%)
Carcinoma, Metastatic, Harderian Gland 2 (4%)
Hepatocellular Carcinoma, Metastatic, Liver 4 (8%) 3 (6%) 2 (4%) 3 (6%)
Hepatocellular Carcinoma, Metastatic, Lung 1 (2%)
Hepatocholangiocarcinoma, Metastatic, Liver 1 (2%) 2 (4%)
Sarcoma, Metastatic, Skin 1 (2%)
Teratoma Malignant, Metastatic, Ovary 1 (2%)
Mediastinum, Carcinoma, Metastatic,
Harderian Gland 1 (2%)
Mediastinum, Hemangioma 1 (2%)
Mediastinum, Hepatocholangiocarcinoma,
Metastatic, Liver 1 (2%) 1 (2%)
Mediastinum, Sarcoma, Metastatic, Skin 1 (2%)
____________________________________________________________________________________________________________________________________
SPECIAL SENSES SYSTEM
Harderian Gland (5) (4) (3) (2)
Adenoma 2 (40%) 3 (75%) 2 (67%) 2 (100%)
Carcinoma 3 (60%) 1 (25%) 1 (33%)
____________________________________________________________________________________________________________________________________
URINARY SYSTEM
Kidney (50) (50) (50) (50)
Hepatocholangiocarcinoma, Metastatic, Liver 1 (2%) 1 (2%)
Teratoma Malignant, Metastatic, Ovary 1 (2%)
Urinary Bladder (48) (48) (50) (48)
Hemangioma 1 (2%)
____________________________________________________________________________________________________________________________________
SYSTEMIC LESIONS
Multiple Organs *(50) *(50) *(50) *(50)
Histiocytic Sarcoma 1 (2%)
* Number of animals with any tissue examined microscopically
Page 5
NTP Experiment-Test: 05180-07 INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a) Report: PEIRPT05
Study Type: CHRONIC GALLIUM ARSENIDE Date: 03/09/99
Route: RESPIRATORY EXPOSURE WHOLE BODY Time: 14:24:40
____________________________________________________________________________________________________________________________________
B6C3F1 MICE FEMALE CONTROL 0.1 0.5 1.0
MG/M3 MG/M3 MG/M3
____________________________________________________________________________________________________________________________________
SYSTEMIC LESIONS - cont
Multiple Organs *(50) *(50) *(50) *(50)
Lymphoma Malignant 3 (6%) 8 (16%) 11 (22%) 10 (20%)
____________________________________________________________________________________________________________________________________
NTP Experiment-Test: 05180-07 INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a) Report: PEIRPT05
Study Type: CHRONIC GALLIUM ARSENIDE Date: 03/09/99
Route: RESPIRATORY EXPOSURE WHOLE BODY Time: 14:24:40
____________________________________________________________________________________________________________________________________
B6C3F1 MICE FEMALE CONTROL 0.1 0.5 1.0
MG/M3 MG/M3 MG/M3
____________________________________________________________________________________________________________________________________
TUMOR SUMMARY
Total Animals with Primary Neoplasms (b) 36 36 40 39
Total Primary Neoplasms 58 59 65 67
Total Animals with Benign Neoplasms 22 24 26 22
Total Benign Neoplasms 28 30 31 35
Total Animals with Malignant Neoplasms 26 23 26 26
Total Malignant Neoplasms 30 29 34 32
Total Animals with Metastatic Neoplasms 9 3 6 7
Total Metastatic Neoplasm 18 3 16 19
Total Animals with Malignant Neoplasms
Uncertain Primary Site
Total Animals with Neoplasms Uncertain-
Benign or Malignant
Total Uncertain Neoplasms
____________________________________________________________________________________________________________________________________
a Number of animals examined microscopically at site and number of animals with lesion
b Primary tumors: all tumors except metastatic tumors
NTP Experiment-Test: 05180-07 INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a) Report: PEIRPT05
Study Type: CHRONIC GALLIUM ARSENIDE Date: 03/09/99
Route: RESPIRATORY EXPOSURE WHOLE BODY Time: 14:24:40
____________________________________________________________________________________________________________________________________
B6C3F1 MICE MALE CONTROL 0.1 0.5 1.0
MG/M3 MG/M3 MG/M3
____________________________________________________________________________________________________________________________________
DISPOSITION SUMMARY
Animals Initially in Study 50 50 50 50
Early Deaths
Moribund Sacrifice 7 8 10 7
Natural Death 8 4 6 9
Survivors
Terminal Sacrifice 35 38 34 34
Animals Examined Microscopically 50 50 50 50
____________________________________________________________________________________________________________________________________
ALIMENTARY SYSTEM
Intestine Large, Cecum (44) (49) (44) (42)
Polyp Adenomatous 1 (2%)
Intestine Small, Duodenum (42) (46) (45) (43)
Histiocytic Sarcoma 1 (2%)
Intestine Small, Jejunum (44) (48) (45) (43)
Carcinoma 2 (5%) 2 (4%) 1 (2%)
Hemangiosarcoma 1 (2%)
Intestine Small, Ileum (44) (47) (45) (42)
Hepatocellular Carcinoma, Metastatic, Liver 1 (2%)
Liver (50) (50) (50) (50)
Hemangiosarcoma 1 (2%) 2 (4%) 3 (6%) 1 (2%)
Hepatocellular Carcinoma 10 (20%) 7 (14%) 10 (20%) 14 (28%)
Hepatocellular Carcinoma, Multiple 3 (6%) 2 (4%) 2 (4%) 3 (6%)
Hepatocellular Adenoma 11 (22%) 13 (26%) 12 (24%) 15 (30%)
Hepatocellular Adenoma, Multiple 5 (10%) 5 (10%) 7 (14%) 2 (4%)
Hepatocholangiocarcinoma 2 (4%)
Histiocytic Sarcoma 2 (4%) 1 (2%)
Mesentery (4) (5) (4) (6)
Hemangioma 1 (25%)
Hemangiosarcoma 2 (50%)
Sarcoma 1 (25%)
Pancreas (50) (50) (49) (47)
Sarcoma, Metastatic, Mesentery 1 (2%)
Stomach, Forestomach (50) (50) (49) (49)
Squamous Cell Papilloma 1 (2%) 1 (2%)
Tooth (1) (3) (1) (1)
Odontoma 1 (33%)
____________________________________________________________________________________________________________________________________
NTP Experiment-Test: 05180-07 INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a) Report: PEIRPT05
Study Type: CHRONIC GALLIUM ARSENIDE Date: 03/09/99
Route: RESPIRATORY EXPOSURE WHOLE BODY Time: 14:24:40
____________________________________________________________________________________________________________________________________
B6C3F1 MICE MALE CONTROL 0.1 0.5 1.0
MG/M3 MG/M3 MG/M3
____________________________________________________________________________________________________________________________________
CARDIOVASCULAR SYSTEM
Heart (50) (50) (50) (50)
Hemangiosarcoma 1 (2%)
____________________________________________________________________________________________________________________________________
ENDOCRINE SYSTEM
Adrenal Cortex (50) (50) (50) (48)
Adenoma 1 (2%)
Histiocytic Sarcoma 1 (2%)
Capsule, Adenoma 1 (2%)
Adrenal Medulla (50) (50) (50) (47)
Pheochromocytoma Benign 1 (2%)
Islets, Pancreatic (50) (48) (49) (47)
Adenoma 3 (6%)
Thyroid Gland (50) (50) (50) (48)
Follicular Cell, Adenoma 1 (2%) 1 (2%)
Follicular Cell, Carcinoma 1 (2%)
____________________________________________________________________________________________________________________________________
GENERAL BODY SYSTEM
None
____________________________________________________________________________________________________________________________________
GENITAL SYSTEM
Epididymis (50) (50) (50) (49)
Prostate (50) (49) (49) (49)
Seminal Vesicle (50) (50) (48) (43)
Hemangioma 1 (2%)
Testes (50) (50) (50) (50)
Hemangioma 1 (2%)
Interstitial Cell, Adenoma 2 (4%)
____________________________________________________________________________________________________________________________________
HEMATOPOIETIC SYSTEM
Bone Marrow (49) (50) (50) (48)
Hemangiosarcoma 2 (4%) 1 (2%)
Lymph Node (2) (2) (1)
Pancreatic, Histiocytic Sarcoma 1 (50%)
Renal, Hemangiosarcoma 1 (100%)
Lymph Node, Bronchial (38) (37) (40) (41)
Histiocytic Sarcoma 1 (2%)
Lymph Node, Mandibular (37) (40) (28) (32)
Histiocytic Sarcoma 1 (3%)
NTP Experiment-Test: 05180-07 INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a) Report: PEIRPT05
Study Type: CHRONIC GALLIUM ARSENIDE Date: 03/09/99
Route: RESPIRATORY EXPOSURE WHOLE BODY Time: 14:24:40
____________________________________________________________________________________________________________________________________
B6C3F1 MICE MALE CONTROL 0.1 0.5 1.0
MG/M3 MG/M3 MG/M3
____________________________________________________________________________________________________________________________________
HEMATOPOIETIC SYSTEM - cont
Lymph Node, Mesenteric (48) (49) (50) (46)
Histiocytic Sarcoma 1 (2%) 1 (2%)
Lymph Node, Mediastinal (38) (36) (38) (33)
Hepatocellular Carcinoma, Metastatic, Liver 1 (3%)
Histiocytic Sarcoma 1 (3%)
Spleen (50) (50) (49) (47)
Hemangiosarcoma 2 (4%) 2 (4%) 1 (2%)
Thymus (38) (36) (38) (35)
____________________________________________________________________________________________________________________________________
INTEGUMENTARY SYSTEM
Skin (50) (50) (50) (50)
Histiocytic Sarcoma 1 (2%)
Sebaceous Gland, Adenoma 1 (2%)
Subcutaneous Tissue, Hemangiosarcoma 1 (2%)
Subcutaneous Tissue, Lipoma 1 (2%) 1 (2%) 1 (2%)
____________________________________________________________________________________________________________________________________
MUSCULOSKELETAL SYSTEM
Bone (49) (50) (50) (50)
Hepatocellular Carcinoma, Metastatic, Liver 1 (2%)
____________________________________________________________________________________________________________________________________
NERVOUS SYSTEM
None
____________________________________________________________________________________________________________________________________
RESPIRATORY SYSTEM
Lung (50) (50) (50) (50)
Alveolar/Bronchiolar Adenoma 12 (24%) 8 (16%) 10 (20%) 6 (12%)
Alveolar/Bronchiolar Adenoma, Multiple 1 (2%) 2 (4%) 1 (2%) 1 (2%)
Alveolar/Bronchiolar Carcinoma 3 (6%) 4 (8%) 6 (12%) 6 (12%)
Alveolar/Bronchiolar Carcinoma, Multiple 2 (4%)
Carcinoma, Metastatic, Harderian Gland 1 (2%) 1 (2%) 1 (2%) 1 (2%)
Hemangiosarcoma 1 (2%)
Hepatocellular Carcinoma, Metastatic, Liver 3 (6%) 1 (2%) 2 (4%) 2 (4%)
Histiocytic Sarcoma 1 (2%) 1 (2%)
Mediastinum, Alveolar/Bronchiolar Carcinoma,
Metastatic, Lung 1 (2%)
Mediastinum, Hepatocellular Carcinoma,
Metastatic, Liver 1 (2%)
____________________________________________________________________________________________________________________________________
NTP Experiment-Test: 05180-07 INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a) Report: PEIRPT05
Study Type: CHRONIC GALLIUM ARSENIDE Date: 03/09/99
Route: RESPIRATORY EXPOSURE WHOLE BODY Time: 14:24:40
____________________________________________________________________________________________________________________________________
B6C3F1 MICE MALE CONTROL 0.1 0.5 1.0
MG/M3 MG/M3 MG/M3
____________________________________________________________________________________________________________________________________
SPECIAL SENSES SYSTEM
Ear (1)
Hemangiosarcoma 1 (100%)
Harderian Gland (47) (48) (49) (48)
Adenoma 3 (6%) 6 (13%) 8 (16%) 8 (17%)
Adenoma, Multiple 1 (2%)
Carcinoma 1 (2%) 1 (2%) 3 (6%) 4 (8%)
____________________________________________________________________________________________________________________________________
URINARY SYSTEM
Kidney (50) (50) (49) (48)
Hepatocellular Carcinoma, Metastatic, Liver 1 (2%)
Sarcoma, Metastatic, Mesentery 1 (2%)
Renal Tubule, Adenoma 1 (2%)
Urinary Bladder (49) (50) (46) (46)
____________________________________________________________________________________________________________________________________
SYSTEMIC LESIONS
Multiple Organs *(50) *(50) *(50) *(50)
Histiocytic Sarcoma 3 (6%) 1 (2%)
Lymphoma Malignant 1 (2%) 1 (2%) 2 (4%) 1 (2%)
____________________________________________________________________________________________________________________________________
* Number of animals with any tissue examined microscopically
Page 11
NTP Experiment-Test: 05180-07 INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a) Report: PEIRPT05
Study Type: CHRONIC GALLIUM ARSENIDE Date: 03/09/99
Route: RESPIRATORY EXPOSURE WHOLE BODY Time: 14:24:40
____________________________________________________________________________________________________________________________________
B6C3F1 MICE MALE CONTROL 0.1 0.5 1.0
MG/M3 MG/M3 MG/M3
____________________________________________________________________________________________________________________________________
TUMOR SUMMARY
Total Animals with Primary Neoplasms (b) 40 37 45 41
Total Primary Neoplasms 69 62 79 71
Total Animals with Benign Neoplasms 30 28 33 28
Total Benign Neoplasms 40 39 44 36
Total Animals with Malignant Neoplasms 23 20 26 29
Total Malignant Neoplasms 29 23 35 35
Total Animals with Metastatic Neoplasms 4 2 5 3
Total Metastatic Neoplasm 9 2 6 3
Total Animals with Malignant Neoplasms
Uncertain Primary Site
Total Animals with Neoplasms Uncertain-
Benign or Malignant
Total Uncertain Neoplasms
____________________________________________________________________________________________________________________________________
a Number of animals examined microscopically at site and number of animals with lesion
b Primary tumors: all tumors except metastatic tumors
------------------------------------------------------------
---------- END OF REPORT ----------
------------------------------------------------------------